Federal Register / Vol. 74, No. 66 / Wednesday, April 8, 2009 / Notices 15995 

AdvisoryCouncil/index.html. The 

completed registration form should be 

submitted by facsimile to Professional 

and Scientific Associates (PSA), the 

logistical support contractor for the 

meeting, at fax number (703) 234–1701 

ATTN: Rebecca Pascoe. Registration can 

also be completed electronically at 

https://www.team-psa.com/dot/ 

spring2009/acbsct/. Individuals without 

access to the Internet who wish to 

register may call Rebecca Pascoe with 

PSA at (703) 234–1747. 

Individuals who plan to attend the 

meeting and need special assistance, 

such as sign language interpretation or 

other reasonable accommodations, 

should notify the ACBSCT Executive 

Secretary, Remy Aronoff, in advance of 

the meeting. Mr. Aronoff may be 

reached by telephone at 301–443–3264, 

e-mail: Remy.Aronoff@hrsa.hhs.gov or 

in writing at the address provided 

below. Management and support 

services for ACBSCT functions are 

provided by the Division of 

Transplantation, Healthcare Systems 

Bureau, Health Resources and Services 

Administration, 5600 Fishers Lane, 

Parklawn Building, Room 12C–06, 

Rockville, Maryland 20857; telephone 

number 301–443–7577. 

After the presentations and Council 

discussions, members of the public will 

have an opportunity to provide 

comments. Because of the Council’s full 

agenda and the timeframe in which to 

cover the agenda topics, public 

comment will be limited. All public 

comments will be included in the 

record of the ACBSCT meeting. Meeting 

summary notes will be made available 

on HRSA’s Program Web site at http:// 

bloodcell.transplant.hrsa.gov/ABOUT/ 

Advisory_Council/index.html. 

Dated: April 1, 2009. 

Alexandra Huttinger, 

Director, Division of Policy Review and 

Coordination. 

[FR Doc. E9–7964 Filed 4–7–09; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Office of Rural Health Policy; Notice of 

Meetings 

Name: Office of Rural Health Policy, 

Health Resources and Services 

Administration (HRSA), HHS. 

Dates and Times: April 24, 2009, 8 a.m.— 

3 p.m. in Albuquerque, NM. May 18, 2009, 

8 a.m.—3 p.m. in Seattle, WA. June 26, 2009, 

8 a.m.—3 p.m. in Omaha, NE. 

Place: The Albuquerque Marriott, 2101 

Louisiana Boulevard, NE., Albuquerque, NM 

87110, Phone: 505–881–6800. 

The Seattle Airport Marriott, 3201 South 

176th Street, Seattle, WA 98188, Phone: 206– 

241–2000. 

The Omaha Marriott, 10220 Regency 

Circle, Omaha, NE 68114, Phone: 402–399– 

9000. 

Status: The meetings will be open to the 

public. 

Purpose: The Office of Rural Health Policy 

(ORHP) will hold a series of meetings to 

gather information on potential definitions of 

the terms Frontier or Remote Areas. 

Currently the most widely used definition 

within the Department of Health and Human 

Services (DHHS) requires that the population 

density of a county consist of six or fewer 

persons per square mile. The use of whole 

counties as the unit of measurement can lead 

to inclusion of large population centers in 

large area counties that still have a low 

overall population density. 

Use of population density alone as a 

measure of remoteness is also inappropriate 

for islands as the population density can far 

exceed 6 persons per square mile even 

though the island is isolated and lacks access 

to services and resources. 

ORHP has used the Rural-Urban 

commuting area (RUCA) codes to identify 

rural areas located in Metropolitan counties. 

Metropolitan counties are defined by the 

Office of Management and Budget of the 

White House but can contain substantial 

rural areas due to geographic barriers, 

distance or other factors. RUCAs are based on 

a sub-county unit, the Census Tract, and take 

into account population density, 

urbanization, and daily commuting patterns. 

Every Census tract is assigned a code based 

on these factors. While ORHP has chosen to 

define Metropolitan tracts with RUCA codes 

from 4 through 10 as ‘‘rural’’ for purposes of 

grant eligibility, the codes have not been 

used to identify ‘‘Frontier’’ or remote areas. 

In order to pursue a more accurate 

definition of Frontier/Remote areas, ORHP 

has entered into agreements with L. Gary 

Hart and the Economic Research Service 

(ERS) of the US Department of Agriculture 

(USDA). Dr. Hart and ERS also developed the 

RUCAs with support from ORHP. As work on 

this definition proceeds ORHP will hold a 

series of meetings to gather information from 

interested parties and the public. 

While a robust, quantitative definition of 

Frontier/Remote areas may have future 

programmatic uses, the immediate goal of 

ORHP and ERS is to make this work available 

for research purposes. 

For Further Information Contact: Direct 

requests for additional information to Mr. 

Steven Hirsch, Health Resources and 

Services Administration, Office of Rural 

Health Policy, Room 9A–55, 5600 Fishers 

Lane, Rockville, MD 20857, (301) 443–7322. 

E-mail: shirsch@hrsa.gov. 

Dated: April 3, 2009. 

Alexandra Huttinger, 

Director, Division of Policy Review and 

Coordination. 

[FR Doc. E9–8013 Filed 4–7–09; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Part C Early Intervention Services 

Grant Under the Ryan White HIV/AIDS 

Program 

AGENCY: Health Resources and Services 

Administration (HHS). 

ACTION: Notice of noncompetitive 

transfer of Part C funds from Cathedral 

Healthcare System to Saint Michael’s 

Medical Center. 

SUMMARY: HRSA will be transferring 

Part C funds to Saint Michael’s Medical 

Center as a noncompetitive replacement 

award in order to ensure continuity of 

critical HIV medical care and treatment 

services and to avoid a disruption of 

HIV clinical care to clients in 

Metropolitan Newark, and Essex County 

in New Jersey. 

SUPPLEMENTARY INFORMATION: Grantee of 

record: Cathedral Healthcare System. 

Intended recipient of the award: Saint 

Michael’s Medical Center, Newark, New 

Jersey. 

Amount of the award: $537,607 to 

ensure ongoing clinical services to the 

target population. 

Authority: Section 2651 of the Public 

Health Service Act, 42 U.S.C. 300ff–51. 

CFDA Number: 93.918. 

Project period: April 1, 2005 to March 

31, 2010. The period of support for the 

replacement award is from April 1, 2009 

to March 31, 2010. 

Justification for the Exception to 

Competition: Critical funding for HIV 

medical care and treatment services to 

clients in Metropolitan Newark and 

Essex County in New Jersey will be 

continued through a noncompetitive 

supplement to Saint Michael’s Medical 

Center, a prior sub-contractor of 

Cathedral Healthcare System, the 

grantee of record in Newark, New 

Jersey. This is a temporary replacement 

award as the previous grant recipient 

serving this population notified HRSA 

that they will not continue providing 

services after March 31, 2009. The 

Cathedral Healthcare System, the former 

grantee, has ceased governance and 

operations of its three hospitals. Saint 

Michael’s Medical Center is the best 

qualified recipient for this supplement, 

as it already serves most of the former 

grantee’s patients ensuring continuity of 

care, and can continue to provide 

critical services with the least amount of 

disruption to the service population 

while the service area is re-competed. 

This supplement will cover the time 

period from April 1, 2009, through 


rwilkins on PROD1PC63 with NOTICES
15996 Federal Register / Vol. 74, No. 66 / Wednesday, April 8, 2009 / Notices 

March 31, 2010. This service area will 

be included in the upcoming 

competition for the Part C HIV Early 

Intervention Services for project periods 

starting April 2010. 

FOR FURTHER INFORMATION CONTACT: 

Maria C. Rios, via e-mail 

mrios@hrsa.gov, or via telephone, 301– 

443–0493. 

Dated: April 2, 2009. 

Marcia K. Brand, 

Acting Deputy Administrator. 

[FR Doc. E9–7963 Filed 4–7–09; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Substituted Triazine and Purine 

Compounds for the Treatment of 

Chagas Disease and African 

Trypanosomiasis 

Description of Invention: Parasitic 

protozoa are responsible for a wide 

variety of infections in both humans and 

animals. Trypanosomiasis poses health 

risks to millions of people across 

multiple countries in Africa and North 

and South America. Visitors to these 

regions, such as business travelers and 

tourists, are also at risk for contracting 

parasitic diseases. There are two types 

of African trypanosomiasis, also known 

as sleeping sickness. One type is caused 

by the parasite Trypanosoma brucei 

gambiense, and the other is caused by 

the parasite Trypanosoma brucei 

rhodesiensi. If left untreated, African 

sleeping sickness results in death. 

Chagas disease, caused by Trypanosoma 

cruzi (T. cruzi), affects millions of 

people in Mexico and South and Central 

America. Untreated, Chagas disease 

causes decreased life expectancy and 

can also result in death. 

The subject invention provides for 

novel triazine and purine compounds 

that are useful for the treatment and 

prevention of mammalian protozoal 

diseases, including African 

trypanosomiasis, Chagas disease and 

other opportunistic infections. The 

compounds can inhibit the cysteine 

proteases rhodesain found in the 

parasites that cause African 

trypanosomiasis and cruzain found in T. 

cruzi. The invention includes 

composition claims for the novel 

triazine and purine compounds, 

methods for inhibiting cruzain or 

rhodesain in a subject, and methods for 

treating subjects suffering from African 

trypanosomiasis or Chagas disease. 

Applications: Prophylactic and 

therapeutic treatment of African 

trypanosomiasis and Chagas disease. 

Advantages: Novel compounds 

against the cysteine proteases, cruzain 

and rhodesain; Compounds possess low 

nanomolar inhibitory potential against 

cruzain and rhodesain. 

Development Status: In vitro and in 

vivo data are available upon request and 

upon execution of an appropriate 

confidentiality agreement. 

Inventors: Craig J. Thomas et al. 

(NHGRI). 

Patent Status: U.S. Provisional 

Application No. 61/199,763 filed 19 

Nov 2008 (HHS Reference No. E–267– 

2008/0–US–01). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; 

changke@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIH Chemical Genomics Center 

(NCGC) is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize appropriate lead 

compounds described in U.S. 

Provisional Application No. 61/199,763. 

Please contact Dr. Craig J. Thomas 

(craigt@nhgri.nih.gov) or Claire Driscoll 

(cdriscol@mail.nih.gov), Director of the 

NHGRI Technology Transfer Office, for 

more information. 

Improved Expression Vectors for 

Mammalian Use 

Description of Invention: This 

technology relates to improving levels of 

gene expression using a combination of 

a constitutive RNA transport element 

(CTE) with a mutant form of another 

RNA transport element (RTE). The 

combination of these elements results in 

a synergistic effect on stability of mRNA 

transcripts, which in turn leads to 

increased expression levels. Using HIV– 

1 gag as reporter mRNA, one mutated 

RTE in combination with a CTE was 

found to improve expression of unstable 

mRNA by about 500-fold. Similarly this 

combination of elements led to 

synergistically elevated levels of HIV–1 

Env expression. The function of CTEs 

and RTEs is conserved in mammalian 

cells, so this technology is a simple and 

useful way of obtaining high levels of 

expression of otherwise poorly 

expressed genes and can be used in a 

number of applications such as but not 

limited to improvements of gene 

therapy vectors, expression vectors for 

mammalian cells. 

Applications: Gene therapy; DNA 

vaccines; Protein expression. 

Development Status: In vitro data 

available. 

Inventor: Barbara K. Felber et al. 

(NCI). 

Patent Status: U.S. Utility Application 

No. 10/557,129 filed 16 Nov 2005, from 

PCT Application No. PCT/US04/15776 

filed 19 May 2004, which published as 

WO 2004/113547 on 29 Dec 2004 (HHS 

Reference No. E–223–2003/1–US–03). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; 

changke@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute Vaccine 

Branch is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. Please 

contact John D. Hewes, Ph.D. at 301– 

435–3121 or hewesj@mail.nih.gov for 

more information. 

Dated: April 1, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–7883 Filed 4–7–09; 8:45 am] 

BILLING CODE 4140–01–P 


rwilkins on PROD1PC63 with NOTICES